Unfractionated Heparin for Hemodialysis: Still the Best Option

被引:72
作者
Cronin, Robert E.
Reilly, Robert F. [1 ]
机构
[1] VA N Texas Hlth Care Syst, Dallas, TX 75216 USA
关键词
LOW-MOLECULAR-WEIGHT; COATED POLYACRYLONITRILE MEMBRANE; INDUCED THROMBOCYTOPENIA; LIPOPROTEIN-LIPASE; RENAL-FAILURE; ANTICOAGULATION; RISK; HYPERKALEMIA; MANAGEMENT; PREGNANCY;
D O I
10.1111/j.1525-139X.2010.00770.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Unfractionated heparin (UFH) is the anticoagulant of choice for most maintenance hemodialysis units in the United States. Low molecular weight heparin (LMWH) is the norm in Western Europe, but is not approved for this indication in the United States. UFH is likely to remain the agent of choice in the United States because of its relative ease of use, safety, and low cost. Coating tubing and dialyzers with heparin is now possible, but systemic anticoagulation with heparin is usually still required. The additional cost of this innovation does not yet justify its use. Side effects of both UFH and LMWH include heparin-induced thrombocytopenia, hypertriglyceridemia, and hyperkalemia. It is uncertain whether osteoporosis is an important side effect, as vitamin D deficiency, secondary hyperparathyroidism, age, and debility are confounding factors. When UFH poses a risk or its use is contraindicated, e. g., after development of heparin-induced thrombocytopenia, the use of direct thrombin inhibitors, regional citrate anticoagulation, citrate dialysate, and heparin-free dialysis may be appropriate.
引用
收藏
页码:510 / 515
页数:6
相关论文
共 49 条
[1]   Citrate for long-term hemodialysis: Prospective study of 1,009 consecutive high-flux treatments in 59 patients [J].
Apsner, R ;
Buchmayer, H ;
Gruber, D ;
Sunder-Plassmann, G .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 45 (03) :557-564
[2]  
BAGDADE JD, 1978, J LAB CLIN MED, V91, P176
[3]   HYPERTRIGLYCERIDEMIA - A METABOLIC CONSEQUENCE OF CHRONIC RENAL FAILURE [J].
BAGDADE, JD ;
PORTE, D ;
BIERMAN, EL .
NEW ENGLAND JOURNAL OF MEDICINE, 1968, 279 (04) :181-+
[4]   Heparin-induced recurrent anaphylaxis [J].
Berkun, Y ;
Haviv, YS ;
Schwartz, LB ;
Shalit, M .
CLINICAL AND EXPERIMENTAL ALLERGY, 2004, 34 (12) :1916-1918
[5]   Pharmacodynamics of unfractionated heparin during and after a hemodialysis session [J].
Brunet, Philippe ;
Simon, Nicolas ;
Opris, Adriana ;
Faure, Valerie ;
Lorec-Penet, Anne-Marie ;
Portugal, Henri ;
Dussol, Bertrand ;
Berland, Yvon .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2008, 51 (05) :789-795
[6]   Timely diagnosis and management of heparin-induced thrombocytopenia in a frequent request, low incidence single centre using clinical 4T's score and particle gel immunoassay [J].
Bryant, Adam ;
Low, Joyce ;
Austin, Steven ;
Joseph, Joanne E. .
BRITISH JOURNAL OF HAEMATOLOGY, 2008, 143 (05) :721-726
[7]   Increased mortality in hemodialysis patients having specific antibodies to the platelet factor 4-heparin complex [J].
Carrier, M. ;
Rodger, M. A. ;
Fergusson, D. ;
Doucette, S. ;
Kovacs, M. J. ;
Moore, J. ;
Kelton, J. G. ;
Knoll, G. A. .
KIDNEY INTERNATIONAL, 2008, 73 (02) :213-219
[8]   HEPARIN FREE DIALYSIS - COMPARATIVE DATA AND RESULTS IN HIGH-RISK PATIENTS [J].
CARUANA, RJ ;
RAJA, RM ;
BUSH, JV ;
KRAMER, MS ;
GOLDSTEIN, SJ .
KIDNEY INTERNATIONAL, 1987, 31 (06) :1351-1355
[9]   The clinical evaluation of low-dose heparin in haemodialysis: a prospective study using the heparin-coated AN69 ST membrane [J].
Chanard, Jacques ;
Lavaud, Sylvie ;
Maheut, Herve ;
Kazes, Isabelle ;
Vitry, Fabien ;
Rieu, Philippe .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2008, 23 (06) :2003-2009
[10]   Is Lipid Control Necessary in Hemodialysis Patients? [J].
Cheung, Alfred K. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 4 :S95-S101